TCBPY (TC BioPharm (Holdings)) Total Receivables: $0.94 Mil (As of Dec. 2024)


What is TC BioPharm (Holdings) Total Receivables?

TC BioPharm (Holdings) TCBPY Total Receivables is $0.94 Mil as of Dec. 2024.

TC BioPharm (Holdings)'s Total Receivables for the quarter that ended in Dec. 2024 was $0.94 Mil.

TC BioPharm (Holdings) Total Receivables Related Terms

TC BioPharm (Holdings) Total Receivables Historical Data

* Premium members only.

The historical data trend for TC BioPharm (Holdings)'s Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings) Total Receivables Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
Get a 7-Day Free Trial 1.66 1.97 2.20 1.56 0.94

TC BioPharm (Holdings) Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.20 3.20 1.56 1.67 0.94

TC BioPharm (Holdings) Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.94 Mil mean?
TC BioPharm (Holdings) (TCBPY) has a Total Receivables of $0.94 Mil as of Dec. 2024. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on TC BioPharm (Holdings) and its competitors.
Is TC BioPharm (Holdings)'s Total Receivables too high?
TC BioPharm (Holdings)'s current Total Receivables is $0.94 Mil.
How does TC BioPharm (Holdings)'s Total Receivables compare to SIGY and CNBX?
TC BioPharm (Holdings)'s Total Receivables of $0.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on TC BioPharm (Holdings) and its competitors. TC BioPharm (Holdings)'s current Total Receivables is $0.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TC BioPharm (Holdings) stock overvalued right now?
TC BioPharm (Holdings) (TCBPY) has a current Total Receivables of $0.94 Mil. The current Total Receivables is $0.94 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For TC BioPharm (Holdings) (TCBPY), the current Total Receivables is $0.94 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TC BioPharm (Holdings) Business Description

Address Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.